H.C. Wainwright analyst Ed Arce maintained a Buy rating on Madrigal Pharmaceuticals Inc (MDGL) today and set a price target of $228. The company’s shares opened today at $126.86, close to its 52-week low of $91.56.
“We continue to expect the initiation of an additional Phase 3 study by mid-2019 in patients with NAFLD (simple steatosis) and early NASH (no fibrosis) and dyslipidemia. Recall, a prior study in patients with heterozygous familial hypercholesterolemia (HeFH), have demonstrated the pleiotropic activity of resmetirom which includes reducing levels of an array of atherogenic lipids; LDL-C, ApoB, triglycerides, ApoCIII, and Lp(a), liver fat and also hs-CRP, all of which are correlated with increased cardiovascular (CV) risk. We continue to believe that resmetirom is very well positioned to demonstrate a strongly favorable CV risk reduction in this much larger patient population and may be approved for dyslipidemia in these patients.”
According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.4% and a 40.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Collegium Pharmaceutical, and Paratek Pharmaceuticals.
Currently, the analyst consensus on Madrigal Pharmaceuticals Inc is a Moderate Buy with an average price target of $158.33, implying a 24.8% upside from current levels. In a report issued on March 20, Oppenheimer also assigned a Buy rating to the stock.
See today’s analyst top recommended stocks >>
Based on Madrigal Pharmaceuticals Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $11.48 million. In comparison, last year the company had a GAAP net loss of $8.45 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia.